Drawing for ONCO

USPTO serial 74412221

ONCO

Reviewed by CopyMark Law Group

Status 601
Filing date
Status date
Registration date
—
Examiner
MICHOS, JOHN E
Law office
FILE REPOSITORY (FRANCONIA)

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with ONCO?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Arthur Schwartz

ARTHUR SCHWARTZ FOLEY & LARDNER3000 K ST NW STE 500WASHINGTON, DC 20007-8696UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
005diagnostic and therapeutic preparations for the diagnosis and treatment of cancer, infectious and autoimmune diseases; and diagnostic reagent kits for medical useABANDONED—
042medical laboratory servicesABANDONED—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Jul 11, 1996ABN1ABANDONMENT - EXPRESS MAILED—
May 30, 1996CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Aug 7, 1995CNSLLETTER OF SUSPENSION MAILED—
Aug 9, 1994CNSLLETTER OF SUSPENSION MAILED—
Jul 12, 1994CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jan 12, 1994CNRTNON-FINAL ACTION MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Nov 4, 1993DOCKASSIGNED TO EXAMINER—
Nov 2, 1993DOCKASSIGNED TO EXAMINER—

Frequently asked questions

Related guidance